Jure Hunt D, Traboulsee A. Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic. Mult Scler J Exp Transl Clin. 2020 Jul 1;6(2):2055217320926613.
Cross H, Sabiq F, Ackermans N, Mattar A, Au S, Woodhall M, Sun B, Devonshire V, Carruthers R, Sayao AL, Bhan V, Schabas A, Chan J, Fritzler M, Waters P, Traboulsee A. Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian Cohort. Front Neurol. 2021 Jan 12;11:525933.
Vavasour IM, Tam R, Li DK, Laule C, Taylor C, Kolind SH, MacKay AL, Javed A, Traboulsee A. A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab. Mult Scler. 2018 Apr 1:1352458518770085.
Metz LM, Li DKB, Traboulsee AL, Duquette P, Eliasziw M, Cerchiaro G, Greenfield J, Riddehough A, Yeung M, Kremenchutzky M, Vorobeychik G, Freedman MS, Bhan V, Blevins G, Marriott JJ, Grand’Maison F, Lee L, Thibault M, Hill MD, Yong VW; Minocycline in MS Study Team. Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. N Engl J Med. 2017 Jun 1;376(22):2122-2133.
Jarrett M, Tam R, Hernández-Torres E, Martin N, Perera W, Zhao Y, Shahinfard E, Dadachanji S, Taunton J, Li DK, Rauscher A. A Prospective Pilot Investigation of Brain Volume, White Matter Hyperintensities, and Hemorrhagic Lesions after Mild Traumatic Brain Injury. Front Neurol. 2016 Feb 12;7:11.
Zhao Y, Kondo Y, Traboulsee A, Li DK, Riddehough A, Petkau AJ. Personalized activity index, a new safety monitoring tool for multiple sclerosis clinical trials. Mult Scler J Exp Transl Clin. 2015 Apr 24;1:2055217315577829.
Dong J, Zhao Y, Petkau AJ, Li DK, Riddehough A, Traboulsee A. Further investigation of safety monitoring guidelines based on magnetic resonance imaging lesion activity in multiple sclerosis clinical trials. Mult Scler. 2015 Jan;21(1):101-4.
Tam RC, Traboulsee A, Riddehough A, Li DK. Improving the clinical correlation of multiple sclerosis black hole volume change by paired-scan analysis. Neuroimage Clin. 2012 Sep 5;1(1):29-36.
McAusland J, Tam RC, Wong E, Riddehough A, Li DK. Optimizing the use of radiologist seed points for improved multiple sclerosis lesion segmentation. IEEE Trans Biomed Eng. 2010 Nov;57(11).
Tam RC, Riddehough A, Li DK. Detection and measurement of coverage loss in interleaved multi-acquisition brain MRIs due to motion-induced inter-slice misalignment. Med Image Anal. 2009 Jun;13(3):381-91.
O’Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R, Teriflunomide Multiple Sclerosis Trial Group, University of British Columbia MS/MRI Research Group. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006 Mar 28;66(6):894-900.
Schwid SR, Thorpe J, Sharief M, Sandbert-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G, EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group, University of British Columbia MS/MRI Research Group. 2005. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE study. Arch Neurol. 2005 May; 62(5):785-792
Freedman MS, Francis GS, Sanders EA, Rice GP, O’Connor P, Comi G, Duquette P, Metz L, Murray TJ, Bouchard JP, Abramsky O, Pelletier J, O’Brien F, Once Weekly Interferon beta-1 alpha for Multiple Sclerosis Study Group, University of British Columbia MS/MRI Research Group. Randomized study of once-weekly interferon beta-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler. 2005 Feb;11(1):41-45
Paty D, Arnason B, Li D, Traboulsee A. Interferons in relapsing remitting multiple sclerosis. Lancet. 2003 May 24;361(9371):1822
Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O’Connor P, Monaghan E, Li D, Weinshenker B, EVIDENCE Study Group: EVidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002 Nov 26; 59(10) 1496-1506
Ebers GC and PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. The Lancet, 1998 Nov 7;352(9139): 1498-1504